

Predictors of long-term intraocular pressure control after lens extraction in primary angle closure glaucoma: results from the EAGLE trial

William G Mitchell ¹, Augusto Azuara-Blanco ^{2,3}, Paul J Foster ⁴, Omar Halawa ^{5,6}, Jennifer Burr ⁷, Craig R Ramsay,⁸ David Cooper,⁹ Claire Cochran,⁸ John Norrie,¹⁰ David Friedman,¹¹ Dolly Chang¹²

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bjophthalmol-2021-319765>).

For numbered affiliations see end of article.

Correspondence to

Professor David Friedman, Ophthalmology, Harvard University, Cambridge, Massachusetts, USA; david_friedman@meei.harvard.edu

DF and DC are joint senior authors.

Received 29 May 2021
Accepted 18 March 2022
Published Online First 6 April 2022

ABSTRACT

Background/aims To assess baseline ocular parameters in the prediction of long-term intraocular pressure (IOP) control after clear lens extraction (CLE) or laser peripheral iridotomy (LPI) in patients with primary angle closure (PAC) disease using data from the Effectiveness of Early Lens Extraction for the treatment of primary angle-closure glaucoma (EAGLE) trial.

Methods This study is a secondary analysis of EAGLE data where we define the primary outcome of 'good responders' as those with IOP < 21 mm Hg without requiring additional surgery and 'optimal responders' as those who in addition were medication free, at 36-month follow-up. Primary analysis was conducted using a multivariate logistic regression model to assess how randomised interventions and ocular parameters predict treatment response.

Results A total of 369 patients (182 in CLE arm and 187 in LPI arm) completed the 36-month follow-up examination. After CLE, 90% met our predefined 'good response' criterion compared with 67% in the LPI arm, and 66% met 'optimal response' criterion compared with 18% in the LPI arm, with significantly longer drops/surgery-free survival time ($p < 0.05$ for all). Patients randomised to CLE (OR = 10.1 (6.1 to 16.8)), Chinese (OR = 2.3 (1.3 to 3.9)), and those who had not previously used glaucoma drops (OR = 2.8 (1.6 to 4.8)) were more likely to maintain long-term optimal IOP response over 36 months.

Conclusion Patients with primary angle closure glaucoma/PAC are 10 times more likely to maintain drop-free good IOP control with initial CLE surgery than LPI. Non-Chinese ethnicity, higher baseline IOP and using glaucoma drops prior to randomisation are predictors of worse long-term IOP response.

INTRODUCTION

In 2016, we published the results of a randomised clinical trial comparing initial clear lens extraction (CLE) to laser peripheral iridotomy (LPI) for primary angle closure (PAC) and primary angle closure glaucoma (PACG) and reported better outcomes with CLE. Those undergoing CLE reported higher mean quality of life scores and had lower mean intraocular pressure (IOP -1.18 mm Hg (95% CI -1.99 to -0.38 , $p = 0.004$)) after intervention, with fewer medications and glaucoma surgery, with an incremental cost effectiveness ratio of £14 284.¹

Key messages

What is already known on this topic

⇒ Clear lens extraction (CLE) has greater efficacy and is more cost-effective than laser peripheral iridotomy (LPI) in patients with primary angle closure (PAC) disease.

What this study adds

⇒ Among patients with PAC disease, we found that those with initial CLE were 10× more likely to maintain good drop-free intraocular pressure (IOP) control over 3 years versus LPI. We also identified Chinese ethnicity, lower preoperative IOP, not using glaucoma drops, and no glaucomatous changes to be baseline factors associated with drop-free postoperative IOP control.

How this study might affect research, practice or policy

⇒ In the context of shifting global management standards for angle closure disease, this study is important in guiding management decisions and further research.

Higher baseline IOP has been shown to predict higher postsurgery IOP for both non-glaucomatous²⁻⁷ and open-angle glaucoma eyes with cataract.^{2 3 8-12} However, understanding which populations with PAC or PACG stand most to benefit from CLE remains to be determined. A recent paper found that higher baseline IOP was a predictor of higher IOP up to 48 months postoperatively for those with PACG and cataract undergoing phacoemulsification surgery.¹³ Assessing *proportionate* change in IOP, others have reported that higher baseline IOP was associated with greater IOP reduction after phacoemulsification surgery, for both non-glaucomatous and glaucomatous eyes with cataract.⁵ Only one paper has reported on anatomic predictors of IOP lowering, reporting that circumferential iridotrabeular contact was the best baseline parameter for prediction of postoperative IOP reduction for patients with PAC and IOP > 30 mm Hg and cataract undergoing surgery.¹⁴

To date, there has been no analysis of predictors of IOP reduction after CLE in patients with non-cataractous lenses in either PAC or PACG. We



© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Mitchell WG, Azuara-Blanco A, Foster PJ, et al. *Br J Ophthalmol* 2023;**107**:1072–1078.

aimed to identify baseline parameters associated with postoperative IOP reduction for those with PAC (with IOP > 30 mm Hg) or PACG undergoing CLE versus LPI, using data from the EAGLE trial up to 36 months postoperatively.

METHODS

Analysis cohort

Details of the EAGLE trial design and baseline characteristics are described elsewhere.^{1 15} In brief, the EAGLE trial was a multicentre, international, randomised controlled trial comparing CLE with LPI. A total of 419 newly diagnosed PAC with IOP ≥ 30 mm Hg or patients with PACG were recruited from 30 hospitals across the UK, mainland China, Singapore, Malaysia, Hong Kong and Australia. PAC was defined as iridotrabeular contact of at least 180° on gonioscopy, and PACG as reproducible glaucomatous visual field (VF) defects, glaucomatous optic neuropathy or both and IOP ≥ 21 mm Hg on at least one occasion. Individuals with symptomatic or clinically significant cataract, advanced glaucoma or previous acute closed-angle glaucoma attacks were excluded.

The trial was prospectively registered with the ISRCTN registry, number ISRCTN44464607. Study participants provided written informed consent. An independent data monitoring committee and an independent trial steering committee provided oversight.

EAGLE procedures

Topical medications started at the time of diagnosis were continued and the allocated interventions were performed within 60 days of randomisation. Participants randomised to CLE underwent phacoemulsification with a monofocal intraocular lens implant. Synechiolysis during lens extraction was allowed according to local practice. Patients randomised to standard of care underwent LPI. Laser iridoplasty was allowed if angle closure persisted after LPI, although this was rare.¹

A target IOP of 15–20 mm Hg was set at baseline dependent on the level of nerve damage.¹⁵ Topical therapy could be escalated after intervention as needed to achieve this target. In the instance that maximal medical therapy did not control the IOP, the ophthalmologist could offer glaucoma surgery (including lens extraction in the LPI group). Patients assigned to LPI could undergo lens extraction for reduced vision (ie, cataract surgery) as well.

EAGLE assessments

Assessments were done at baseline and 6, 12, 24 and 36 months after randomisation. IOP was the average of two readings by Goldmann tonometry. Two observers at each site, following a masking protocol, were involved in the IOP measurements. Best-corrected visual acuity was tested using the ETDRS vision charts. The extent of peripheral anterior synechiae (PAS) and iridotrabeular contact were determined by gonioscopy. Anterior chamber measurements (axial length (AL) and anterior chamber depth (ACD)) were performed using an IOLMaster. Participants underwent two VF tests at baseline, and one at 6, 12, 24 and 36 months using a standard automated perimetry test (Humphrey SITA 24-2 test). Further detail of the original EAGLE procedures and assessments can be found in the original trial.¹

Definition of success

For the present study, we defined ‘good responders’ as those with an IOP < 21 mm Hg and without additional glaucoma surgery or lens extraction (vs all others, termed ‘poor responders’). We

further defined ‘optimal responders’ as those with an IOP < 21 mm Hg and without glaucoma surgery or lens extraction, who were additionally using no topical glaucoma medications at 36 months postoperatively (vs all others, termed ‘suboptimal responders’). In sensitivity analyses, patients in the LPI arm who underwent subsequent lens extraction (LE) for low vision (ie, cataract) rather than glaucoma management (with an IOP < 21 mm Hg) were not considered treatment failure. We also performed survival analysis assessing time to treatment failure, which was defined as either IOP ≥ 21 mm Hg, needing additional topical medications after intervention, or requiring an additional glaucoma surgery or lens extraction in the originally treated eye.

Statistical analyses

All analyses were based on complete case analysis principles and no imputation was performed for missing data. Only the study eye of each patient was included in the analyses. The following baseline parameters were assessed: race, age, gender, diagnosis (PAC vs PACG), VF loss (Mean Deviation Index), visual acuity, baseline IOP, ACD, PAS, glaucoma medications.

Outcome measurements were compared by t-tests for continuous outcome variables, and χ^2 tests for dichotomous outcome variables. Univariate and multivariate logistic regression models were used to assess the association between baseline characteristics and the response to interventions. HRs with 95% CIs were estimated using a Cox proportional hazards model between eyes randomised to CLE versus LPI. We used Kaplan-Meier survival curves to display failure rates, where failure was defined as either (1) IOP > 21 mm Hg, (2) reoperation or (3) the need for medications to control IOP, and log-rank tests to test for equality of survival curves. All statistical analyses were performed using Stata V.14.2. The significance level was set at 5% in all analyses.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, interpretation or writing of the report.

RESULTS

Among 419 randomised participants, a total of 369 (182 in CLE arm and 187 in LPI arm) completed the 36-month follow-up or were censored owing to having undergone additional surgeries. Only 1 study eye randomised to CLE underwent trabeculectomy

Table 1 Treatment response by visits

	CLE	LPI
Good response		
6-month visit (n (%))	179 (91.8)	129 (63.9)
12-month visit (n (%))	178 (92.7)	121 (62.1)
24-month visit (n (%))	161 (86.6)	108 (58.1)
36-month visit (n (%))	163 (89.6)	125 (66.8)
Optimal response		
6-month visit (n (%))	130 (66.7)	43 (21.3)
12-month visit (n (%))	136 (70.8)	42 (21.4)
24-month visit (n (%))	121 (65.1)	35 (18.8)
36-month visit (n (%))	120 (63.9)	33 (17.7)
Good response defined by intraocular pressure (IOP) < 21 mm Hg and not had additional lens extraction or glaucoma surgery at each visit.		
Optimal response defined by IOP < 21 mm Hg without any medication and has not had additional lens extraction or glaucoma surgery at each visit.		
CLE, clear lens extraction; LPI, laser peripheral iridotomy.		




Figure 1 Interval intraocular pressure change for clear lens extraction versus laser peripheral iridotomy (LPI).

to control IOP (0.5%) while 6 had trabeculectomy (2.8%) and 29 underwent lens extraction (13.7%) in the LPI arm.

CLE resulted in greater long-term IOP reduction than LPI. 89.6% of eyes had good pressure control after CLE with concurrent topical IOP-lowering medication, and 65.9% of them did not require topical glaucoma drops at 36 months. Among the LPI arm, 66.8% had good IOP control at 36 months with concurrent glaucoma drops, and only 17.7% of them remained off IOP lowering drops at 36 months (table 1). Interval IOP between CLE versus LPI is shown in figure 1. Despite similar IOP between CLE versus LPI at each interval, there was a substantially lower need for drops to control IOP for the CLE arm at 36 months.

After initial CLE, good responders were more likely to be of Chinese ethnicity (30.7% for good responder versus 0% for

poor responder, $p=0.005$) and have shallower ACD (2.53 mm vs 2.71 mm, $p=0.03$) than poor responders (table 2A); and optimal responders more likely to have shallower ACD (2.51 mm vs 2.61 mm, $p=0.048$) and be drop-free at baseline ($p=0.04$) than suboptimal responders (table 2B). Patients who were not prescribed any glaucoma drops at baseline were more likely to be drops free after both CLE ($p=0.04$) and LPI ($p=0.01$, table 2B). After LPI, good responders were more likely to have lower IOP at baseline (29.6 mm Hg for good responders vs 32.3 mm Hg for poor responders, $p=0.02$) compared with poor responders; and optimal responders were more likely to be of Chinese ethnicity ($p=0.01$), more likely to have had PAC and less likely PACG ($p<0.001$), and lower refractive error (spherical equivalence +0.40D versus +1.48D, $p=0.02$) compared with suboptimal responders (table 2B). Sensitivity analyses demonstrated similar associations between Chinese ethnicity and PAC (rather than PACG) and optimal response after LPI (online supplemental table S1). In contrast to the CLE cohort, baseline ACD was not associated with optimal response after LPI. There was otherwise no statistically significant difference in age, gender, gonioscopic findings, AL, VF, visual acuity or central corneal thickness measurement at baseline between good versus poor responders or optimal versus suboptimal responders for either group.

The 3-year failure rate was 38% after initial CLE and 72% after initial LPI ($p<0.001$, figure 2). The LPI-treated eyes had a >2.5 times higher risk of failure compared with those treated initially with CLE over 36 months ($p<0.001$) (table 3). Non-Chinese (HR=1.52 (1.14–2.05)), those who had used glaucoma drops before randomisation (HR=1.48 (1.12–1.95)) and those who had higher baseline IOP (HR=1.08 (1.01–1.16) per 5 mm Hg) were at higher risk of failure (table 3). In multivariate logistic regression, patients of Chinese origin (OR=2.26, 95% CI 1.31 to 3.89), with PAC (OR=2.10, 95% CI 1.26 to 3.49), on no glaucoma drops (OR=2.77 (1.61 to 4.78)) and with better

Table 2A Baseline demographics by responding to clear lens extraction (CLE) versus laser peripheral iridotomy (LPI)

	CLE (n=182)		LPI (n=187)	
	Good responder	Poor responder	Good responder	Poor responder
Number (%)	163 (89.6%)	19 (10.4%)	125 (66.8%)	62 (33.2%)
Age (mean±SD)	68.1±8.1	66.5±6.8	66.7±8.5	68.5±8.2
Female (n (%))	93 (57.1%)	14 (73.7%)	68 (54.4%)	38 (61.3%)
Chinese origin (n (%))	50 (30.7%)*	0 (0%)*	38 (30.4%)	18 (29.0%)
Diagnosis (n (%))				
PAC	64 (39.3%)	9 (47.4%)	50 (40.0%)	23 (37.1%)
PACG	99 (60.7%)	10 (52.6%)	75 (60.0%)	39 (62.9%)
Spherical equivalence, D (mean±SD)	+1.66±2.44	+1.64±1.29	+1.27±2.34	+1.34±2.26
Glaucoma medication used at baseline (n (%))	95 (61.3%)	12 (63.2%)	76 (63.3%)	42 (68.9%)
Gonioscopy measurements				
Peripheral anterior synechiae, degree (mean±SD)	42.4±78.7	14.2±43.2	46.0±80.9	38.6±72.3
Irido-trabecular contact, degree (mean±SD)	292.5±79.1	264.7±74.4	303.7±72.1	306.1±72.6
IOLMaster (mean±SD)				
Axial length, mm	22.53±0.93	22.69±0.56	22.59±0.98	22.71±1.05
Anterior chamber depth, mm	2.53±0.32*	2.71±0.31*	2.54±0.34	2.55±0.42
Visual fields MD, dB (mean±SD)	-4.89±5.30	-2.44±5.07	-4.14±4.47	-5.57±6.22
Visual acuity, ETDRS letter	76.8±11.8	77.4±20.5	76.0±14.2	74.5±14.1
Intraocular pressure, mm Hg (mean±SD)	29.64±8.13	29.47±7.19	29.59±6.87*	32.31±9.18*
Central corneal thickness, ±m (mean±SD)	550.1±38.0	557.6±40.9	554.9±41.5	545.6±36.6

Good responder defined by intraocular pressure <21 mm Hg at 36 months and not had additional lens extraction or glaucoma surgery.

* = statistically significantly different, $p < 0.05$.

MD, mean deviation; PAC, primary angle closure; PACG, primary angle closure glaucoma.

Table 2B Baseline demographics by responding to clear lens extraction (CLE) versus laser peripheral iridotomy (LPI); optimal responder defined by intraocular pressure <21 at 36 months without any medication and no additional surgery

	CLE (n=182)		LPI (n=187)	
	Optimal responder	Suboptimal responder	Optimal responder	Suboptimal responder
Number (%)	120 (65.9%)	62 (34.1%)	33 (17.7%)	154 (82.4%)
Age (mean±SD)	67.6±8.1	68.6±7.9	65.6±9.2	67.6±8.3
Female (n (%))	69 (57.5%)	38 (61.3%)	23 (69.7%)	83 (53.9%)
Chinese origin (n (%))	38 (31.7%)	12 (19.4%)	16 (48.5%)*	40 (26.0%)*
Diagnosis (n (%))				
PAC	52 (43.3%)	21 (33.9%)	22 (66.7%)*	51 (33.1%)*
PACG	68 (56.7%)	41 (66.1%)	11 (33.3%)*	103 (66.9%)*
Spherical equivalence, D (mean±SD)	+1.79±2.33	+1.43±2.36	+0.40±2.58*	+1.48±2.21*
Glaucoma medication used at baseline(n (%))	65 (56.0%)*	42 (72.4%)*	14 (45.2%)*	104 (69.3%)*
Gonioscopy measurements				
Peripheral anterior synechiae, degree (mean±SD)	45.7±79.6	27.6±68.3	38.8±65.1	44.5±80.6
Irido-trabecular contact, degree (mean±SD)	290.1±81.9	289.1±73.4	323.4±55.3	300.3±74.8
IOLMaster (mean±SD)				
Axial length, mm	22.5±0.9	22.7±0.9	22.7±1.3	22.6±0.9
Anterior chamber depth, mm	2.51±0.34*	2.61±0.29*	2.52±0.46	2.55±0.34
Visual fields MD, dB (mean±SD)	-4.34±5.10	-5.20±5.73	-3.42±3.90	-4.87±5.35
Visual acuity, letter	78.0±10.2	74.7±16.8	73.9±15.4	75.9±13.8
Intraocular pressure, mm Hg (mean±SD)	29.3±8.5	30.3±7.0	30.8±7.1	30.4±8.0
Central corneal thickness, µm (mean±SD)	550.2±38.1	552.3±38.8	560.3±38.8	550.0±40.2

* = statistically significantly different, p < 0.05.
MD, mean deviation; PAC, primary angle closure; PACG, primary angle closure glaucoma.

VF measurements at baseline (OR=1.06, 95% CI 1.01 to 1.12 per 1 dB better) were more likely to be optimal responders at 36 months (table 4). Other baseline characteristics such as age, gender, presence of PAS, ACD and visual acuity were not associated with long-term IOP control.

Among patients randomised to initial CLE, shallower ACD (OR=1.18, 95% CI 1.02 to 1.36 per 0.1 mm shorter), not on glaucoma medications at baseline (OR=2.25, 95% CI 1.12 to 4.54) and worse visual acuity (OR=0.88, 95% CI 0.77 to 1.00 per 1 line worsen) were predictors for either good or optimal response after surgery (table 5). Among patients who were


randomised to initial LPI, Chinese-origin (OR=2.76, 95% CI 1.26 to 6.05), PAC (OR=3.80, 95% CI 1.67 to 8.63), no glaucoma medications at baseline (OR=4.62 (1.86–11.48)), better baseline VF (OR=1.12, 95% CI 1.00 to 1.25 per 1 dB better) and lower baseline IOP (OR=1.30, 95% CI 1.05 to 1.60 per 1 mm Hg lower) were factors associated with either good or optimal long-term IOP control (table 5).

DISCUSSION

In the EAGLE trial, patients undergoing initial CLE were almost 5 times more likely to have better long-term IOP control and 10 times more likely to be free of drops or surgery as compared with those undergoing LPI as initial management of PAC with high IOP or PACG with IOP 21 mm Hg or greater (table 4). Chinese ethnicity, no glaucomatous damage, lower preoperative IOP and no glaucoma medications at baseline were associated with a higher probability of achieving adequate IOP control without the need for daily medications regardless of initial treatment (table 4).

Despite the real difference in IOP reduction between CLE versus LPI being small at 36 months (1 mm Hg), there was a substantially lower need for drops to control IOP for the CLE arm. While no other trials describe the effect of CLE on long-term IOP outcomes in PAC or PACG to our knowledge, others also describe significant IOP reduction following standalone cataract extraction for PAC or PACG at 6–24 months postoperatively, between -1.8 and -8.3 mm Hg.^{16–19}

A shallower anterior chamber has been associated with greater IOP reduction after surgery for patients with PACG and cataract,¹³ in agreement with findings here for those randomised to CLE. A recent study of 18 patients with PAC in a tertiary centre in India undergoing cataract surgery with baseline IOP >30 mm Hg found that greater preoperative iridotrabecular contact was associated with a greater proportionate drop in IOI.¹⁴ We did not



Number at risk	Baseline	6 months	12 months	24 months	36 months
CLE	208	143	139	132	129
LPI	211	52	46	39	38

Log rank test for equality of failure function: p-value<0.001
CLE, clear lens extraction; LPI, laser peripheral iridotomy.

Figure 2 Time to failure over time by intervention. Failure is defined as intraocular pressure >21 or needing medication or surgery. CLE, clear lens extraction; LPI, laser peripheral iridotomy.

Table 3 Predictors associated with failure using Cox proportional hazards model

	Univariate		Multivariate*	
	HR (95% CI)	P value	HR (95% CI)	P value
Intervention (LPI vs CLE)	2.48 (1.89 to 3.25)	<0.001	2.52 (1.92 to 3.31)	<0.001
Age (per 10 years older)	1.12 (0.97 to 1.30)	0.135	1.13 (0.97 to 1.31)	0.107
Female	1.01 (0.79 to 1.30)	0.945	1.01 (0.79 to 1.30)	0.932
Non-Chinese	1.49 (1.11 to 2.00)	0.008	1.52 (1.14 to 2.05)	0.005
PACG (vs PAC)	1.27 (0.98 to 1.65)	0.069	1.19 (0.92 to 1.55)	0.193
PAS (per 30° increase)	0.81 (0.61 to 1.07)	0.142	0.87 (0.65 to 1.16)	0.335
ACD (per 0.1 mm shorter)	0.98 (0.95 to 1.01)	0.309	0.99 (0.95 to 1.03)	0.566
Glaucoma medication at baseline	1.37 (1.04 to 1.80)	0.024	1.48 (1.12 to 1.95)	0.006
Visual field MD (per 1 dB worsen)	1.01 (0.99 to 1.03)	0.321	1.02 (0.99 to 1.04)	0.166
Visual acuity (per 1 line worsen)	1.00 (0.96 to 1.05)	0.950	1.00 (0.96 to 1.05)	0.971
IOP (per 5 mm Hg higher)	1.07 (0.99 to 1.15)	0.070	1.08 (1.01 to 1.16)	0.029

Failure is defined as intraocular pressure (IOP)>21 or needing medication or surgery.

*All multivariate analyses adjusted for intervention, age, gender and race.

ACD, anterior chamber depth; CLE, clear lens extraction; LPI, laser peripheral iridotomy; MD, mean deviation; PAC, primary angle closure; PACG, primary angle closure glaucoma; PAS, peripheral anterior synechia.

find this to be the case in the current study, possibly due to our larger, more diverse patient population that included patients with PAC and PACG and different ethnicities. The authors did not report on concurrent medical therapy requirements for IOP control postoperatively, and only reported 1-month postoperative data.

Similar to previous studies, we found that higher baseline IOP was associated with poorer IOP outcomes for those undergoing either CLE or LPI. Given our IOP success threshold of <21 mm Hg, it is not surprising that those with higher baseline IOP were *less* likely than those with lower baseline IOP to fall below this benchmark at 36 months postoperatively. This finding has also been reported by others. A recent paper on long-term IOP outcomes for those undergoing cataract surgery for PACG found that higher baseline IOP was associated with higher IOP postoperatively.¹³ Others have also described the association between baseline IOP and postoperative IOP control

after cataract surgery, although not for those undergoing CLE or in the setting of glaucoma management exclusively. In these studies, higher baseline IOP was reported to be associated with higher postoperative IOP after cataract surgery,²⁰ and associated with greater proportionate IOP reduction after cataract surgery.⁹ An important limitation for direct comparisons between these studies and our own is that none of the abovementioned studies explicitly report whether good postoperative IOP control was contingent on concurrent topical medication use.

Chinese ethnicity was identified as a predictor for better overall IOP response in this study. All Chinese patients were able to maintain IOP<21 mm Hg for 3 years after CLE (table 2) and Chinese patients were two times more likely to be drops free after either CLE or LPI as compared with non-Chinese patients (table 4). While few have examined the effect of ethnicity on IOP reduction after lens extraction, those that have similarly describe Asian ethnicity to be associated with postoperative

Table 4 Multivariate analyses for baseline predictive factors of good response (intraocular pressure (IOP)<21, no additional surgery) and optimal response (IOP<21, on no medications and no additional surgery) at long-term follow-up (36 months)

	Good response (IOP<21 mm Hg and no surgery)		Optimal response (IOP<21 mm Hg and no medication or surgery)	
	OR (95% CI)	P value	OR (95% CI)	P value
Lens extraction (vs LPI)	4.90 (1.01 to 3.57)	0.046	10.13 (6.10 to 16.83)	<0.001
Age (per 10 years older)	0.88 (0.64 to 1.20)	0.412	0.82 (0.61 to 1.10)	0.191
Female	0.66 (0.38 to 1.12)	0.121	1.17 (0.72 to 1.91)	0.531
Chinese	1.68 (0.92 to 3.08)	0.094	2.26 (1.31 to 3.89)	0.003
PAC (vs PACG)	0.93 (0.54 to 1.59)	0.785	2.10 (1.26 to 3.49)	0.005
PAS (per 30° increase)	1.18 (0.64 to 2.18)	0.596	1.49 (0.86 to 2.58)	0.156
Irido-trabecular contact (per 30°)	1.01 (0.90 to 1.12)	0.915	1.02 (0.93 to 1.13)	0.632
Axial length (per 1 mm shorter)	1.23 (0.93 to 1.61)	0.147	1.15 (0.88 to 1.51)	0.297
ACD (per 0.1 mm shorter)	1.04 (0.96 to 1.12)	0.322	1.05 (0.97 to 1.13)	0.209
Spherical equivalence (+1 D)	1.03 (0.91 to 1.16)	0.673	1.01 (0.91 to 1.14)	0.810
No glaucoma medication	1.39 (0.79 to 2.44)	0.259	2.77 (1.61 to 4.78)	<0.001
Visual field MD (per 1 dB better)	1.02 (0.97 to 1.07)	0.425	1.06 (1.01 to 1.12)	0.022
Visual acuity (per 1 line worsen)	0.96 (0.87 to 1.05)	0.348	0.94 (0.85 to 1.03)	0.190
IOP (per 5 mm Hg lower)	1.21 (1.02 to 1.42)	0.026	0.93 (0.79 to 1.08)	0.333

*All multivariate analyses adjusted for lens extraction, age, gender, ethnicity.

ACD, anterior chamber depth; LPI, laser peripheral iridotomy; MD, mean deviation; PAC, primary angle closure; PACG, primary angle closure glaucoma; PAS, peripheral anterior synechia.

Table 5 Multivariate analyses for baseline predictive factors of good response (intraocular pressure (IOP)<21, no additional surgery) and optimal response (IOP<21, on no medications and no additional surgery) at 36 months, by treatment arm

	Clear lens extraction				Laser peripheral iridotomy			
	Good response		Optimal response		Good response		Optimal response	
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Age (per 10 years older)	1.22 (0.66 to 2.25)	0.524	0.86 (0.58 to 1.28)	0.455	0.77 (0.53 to 1.11)	0.165	0.72 (0.45 to 1.15)	0.173
Female	0.49 (0.17 to 1.44)	0.194	0.84 (0.45 to 1.60)	0.602	0.75 (0.40 to 1.40)	0.372	2.00 (0.88 to 4.57)	0.100
Chinese	---	---	1.89 (0.90 to 3.97)	0.092	1.09 (0.55 to 2.13)	0.812	2.76 (1.26 to 6.05)	0.011
PAC (vs PACG)	0.79 (0.29 to 2.11)	0.633	1.42 (0.73 to 2.75)	0.299	1.09 (0.58 to 2.06)	0.787	3.80 (1.67 to 8.63)	0.001
PAS (per 30° increase)	2.23 (0.61 to 8.18)	0.228	1.80 (0.85 to 3.82)	0.126	1.03 (0.50 to 2.11)	0.934	1.14 (0.48 to 2.67)	0.771
Irido-trabecular contact (per 30°)	1.11 (0.94 to 1.32)	0.212	0.98 (0.86 to 1.10)	0.717	0.97 (0.85 to 1.12)	0.715	1.15 (0.94 to 1.40)	0.171
Axial length (per 1 mm shorter)	1.41 (0.80 to 2.48)	0.239	1.42 (0.97 to 2.07)	0.070	1.15 (0.84 to 1.58)	0.374	0.94 (0.63 to 1.40)	0.761
ACD (per 0.1 mm shorter)	1.18 (1.02 to 1.36)	0.030	1.09 (0.99 to 1.21)	0.090	1.00 (0.92 to 1.09)	0.926	1.00 (0.90 to 1.10)	0.941
Spherical equivalence (+1 D)	1.02 (0.83 to 1.25)	0.848	1.13 (0.97 to 1.31)	0.105	1.00 (0.86 to 1.15)	0.952	0.86 (0.70 to 1.05)	0.137
No glaucoma medication	1.09 (0.40 to 2.97)	0.868	2.25 (1.12 to 4.54)	0.024	1.44 (0.73 to 2.86)	0.297	4.62 (1.86 to 11.48)	0.001
Visual field MD (per 1 dB better)	0.90 (0.78 to 1.02)	0.109	1.05 (0.99 to 1.12)	0.122	1.05 (0.99 to 1.12)	0.092	1.12 (1.00 to 1.25)	0.045
Visual acuity (per 1 line worsen)	1.00 (0.83 to 1.22)	0.972	0.88 (0.77 to 1.00)	0.048	0.96 (0.86 to 1.08)	0.516	1.03 (0.89 to 1.18)	0.712
IOP (per 5 mm Hg lower)	0.97 (0.71 to 1.34)	0.861	1.13 (0.93 to 1.38)	0.224	1.30 (1.05 to 1.60)	0.017	1.02 (0.80 to 1.30)	0.876

*All multivariate analyses adjusted for age, gender (and Chinese).

ACD, anterior chamber depth; MD, mean deviation; PAC, primary angle closure; PACG, primary angle closure glaucoma; PAS, peripheral anterior synechiae.

IOP reduction versus non-Asian ethnicity (although for cataractous lenses).²⁰ Our findings are particularly important given the preponderance of PACG over POAG in East Asian populations, who account for around half of all glaucoma sufferers worldwide.²¹ The prevalence of PACG in East Asia has been attributed toward a number of biometric factors including shallow ACD, lens thickness and shorter AL.²¹ These factors may in part explain why both CLE and LPI were of particular benefit for patients of Chinese ethnicity here, decreasing lens thickness and deepening ACD.

Last, better baseline VF was predictive of optimal IOP control for those undergoing LPI (although not reaching significance in sensitivity analyses). While better preoperative VF may be reflective of less severe disease and preserved integrity of angle structures at baseline—with subsequently greater likelihood of response—this has not been well-described elsewhere.²² Poor baseline VA was associated with lower likelihood of optimal response for those undergoing CLE, also possibly reflective of those with more advanced disease at baseline (and greater structural angle damage) being less likely to benefit from CLE.

The EAGLE trial is a prospective randomised multicentre trial that employed masking of the IOP outcome measure, collected data in a standard fashion (although missing baseline gonioscopic data for 247 patients), and included patients operated on by many surgeons across the globe.²³ We also had good follow-up over 36 months with 88% completed 36-month visit or censored due to additional surgery. That said, the findings only apply to individuals meeting the enrolment criteria for the current study and the results may not be applicable to PAC suspects with IOP below 30 mm Hg or those with PACG and IOP<21 mm Hg. Further, those with symptomatic cataract were ineligible for this trial, and therefore it is not certain that the current findings translate to those with cataractous lens changes. Notably, of the 29 in the LPI arm who underwent subsequent lens extraction, 12 (6%) underwent surgery for clinically significant cataract rather than IOP control.¹ While not controlled for, given the demonstrated effect of lens extraction on IOP and the lower need for drops, this would have reduced our ability to detect a difference between the two arms. Sensitivity analyses also show similar associations between LPI and

optimal response. Variable postoperative IOP goals dictating drops or reoperation may have made those with higher acceptable IOP (closer to 20 than 15 mm Hg) more likely to be both good and optimal responders.¹⁵ However, details of IOP goals were not available as a covariable for the current study and should affect both LPI and CLE arms equally.

We have previously reported that in this multicentre randomised controlled trial, CLE had greater efficacy and was more cost-effective than LPI in patients with PAC disease. Here, we demonstrate that those undergoing CLE were 10 times more likely to achieve IOP control postoperatively without the need for topical therapy or surgery up to 3 years. For those undergoing any intervention, we identified Chinese ethnicity, lower preoperative IOP, not using glaucoma drops at randomisation, and no glaucomatous changes (PAC) are baseline factors associated with optimal postoperative response. This study is of particular importance in the context of shifting global management standards for angle closure disease—and useful in guiding management decisions and further research.

Author affiliations

¹Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA

²Centre for Public Health, Queen's University Belfast, Belfast, UK

³Queen's University Belfast, Centre for Public Health, Belfast, UK

⁴NIHR Biomedical Research Centre, Moorfields Eye Hospital, Institute of

Ophthalmology, University College London, London, UK

⁵Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA

⁶Harvard Medical School, Harvard University, Boston, Massachusetts, USA

⁷School of Medicine, University of St Andrews, St Andrews, UK

⁸Health Services Research Unit, University of Aberdeen, Aberdeen, UK

⁹Health Services Research Unit, University of Aberdeen College of Life Sciences and Medicine, Aberdeen, UK

¹⁰Centre for Health Care Randomised Trials, University of Aberdeen, Aberdeen, UK

¹¹Ophthalmology, Harvard University, Cambridge, Massachusetts, USA

¹²Early Clinical Development, Genentech Inc, South San Francisco, California, USA

Twitter Omar Halawa @oahalawa

Contributors WGM, DF and DSC were responsible for conceptualisation and methodology and were responsible for initial manuscript composition. AA-B, PJF, JB, CRR, DC, CC and JN were responsible for the original investigation and data curation. DSC was responsible for data analyses and validation. DF is guarantor.

Funding Medical Research Council, United Kingdom. DSC is an employee of Genentech, Inc but all work was performed outside the realm of her employment relationship.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The original EAGLE study adhered to the tenets of the Declaration of Helsinki and was approved by local institutional review boards.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

William G Mitchell <http://orcid.org/0000-0002-2122-6741>

Augusto Azuara-Blanco <http://orcid.org/0000-0002-4805-9322>

Paul J Foster <http://orcid.org/0000-0002-4755-177X>

Omar Halawa <http://orcid.org/0000-0002-5245-4034>

Jennifer Burr <http://orcid.org/0000-0002-9478-738X>

REFERENCES

- Azuara-Blanco A, Burr J, Ramsay C, *et al*. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (Eagle): a randomised controlled trial. *The Lancet* 2016;388:1389–97.
- Shrivastava A, Singh K. The effect of cataract extraction on intraocular pressure. *Curr Opin Ophthalmol* 2010;21:118–22.
- Shingleton BJ, Pasternack JJ, Hung JW, *et al*. Three and five year changes in intraocular pressures after clear corneal phacoemulsification in open angle glaucoma patients, glaucoma suspects, and normal patients. *J Glaucoma* 2006;15:494–8.
- Issa SA, Pacheco J, Mahmood U, *et al*. A novel index for predicting intraocular pressure reduction following cataract surgery. *Br J Ophthalmol* 2005;89:543–6.
- Poley BJ, Lindstrom RL, Samuelson TW, *et al*. Intraocular pressure reduction after phacoemulsification with intraocular lens implantation in glaucomatous and nonglaucomatous eyes. *J Cataract Refract Surg* 2009;35:1946–55.
- Moghimi S, Abdi F, Latifi G, *et al*. Lens parameters as predictors of intraocular pressure changes after phacoemulsification. *Eye* 2015;29:1469–76.
- Yang HS, Lee J, Choi S. Ocular biometric parameters associated with intraocular pressure reduction after cataract surgery in normal eyes. *Am J Ophthalmol* 2013;156:89–94.
- Chen PP, Lin SC, Junk AK, *et al*. The effect of phacoemulsification on intraocular pressure in glaucoma patients: a report by the American Academy of ophthalmology. *Ophthalmology* 2015;122:1294–307.
- Poley BJ, Lindstrom RL, Samuelson TW, *et al*. Intraocular pressure reduction after phacoemulsification with intraocular lens implantation in glaucomatous and nonglaucomatous eyes: evaluation of a causal relationship between the natural lens and open-angle glaucoma. *J Cataract Refract Surg* 2009;35:1946–55.
- Shingleton BJ, Gamell LS, O'Donoghue MW, *et al*. Long-Term changes in intraocular pressure after clear corneal phacoemulsification: normal patients versus glaucoma suspect and glaucoma patients. *J Cataract Refract Surg* 1999;25:885–90.
- Mathalone N, Hyams M, Neiman S, *et al*. Long-Term intraocular pressure control after clear corneal phacoemulsification in glaucoma patients. *J Cataract Refract Surg* 2005;31:479–83.
- Hayashi K, Hayashi H, Nakao F, *et al*. Changes in anterior chamber angle width and depth after intraocular lens implantation in eyes with glaucoma. *Ophthalmology* 2000;107:698–703.
- Liu CJ-L, Cheng C-Y, Ko Y-C, *et al*. Determinants of long-term intraocular pressure after phacoemulsification in primary angle-closure glaucoma. *J Glaucoma* 2011;20:566–70.
- Selvan H, Angmo D, Tomar AS, *et al*. Changes in intraocular pressure and angle status after phacoemulsification in primary angle closure hypertension. *J Glaucoma* 2019;28:105–10.
- Azuara-Blanco A, Burr JM, Cochran C, *et al*. The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (Eagle): study protocol for a randomized controlled trial. *Trials* 2011;12:1–10.
- Husain R, Do T, Lai J, *et al*. Efficacy of phacoemulsification alone vs phacoemulsification with goniosynechialysis in patients with primary angle-closure disease: a randomized clinical trial. *JAMA Ophthalmol* 2019;137:1107–13.
- Tham CCY, Kwong YYY, Leung DY, *et al*. Phacoemulsification versus combined phacotrabeculectomy in medically controlled chronic angle closure glaucoma with cataract. *Ophthalmology* 2008;115:2167–73.
- Tham CCY, Kwong YYY, Leung DY, *et al*. Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts. *Ophthalmology* 2009;116:725–31.
- Ong AY, Ng SM, Vedula SS, *et al*. Lens extraction for chronic angle-closure glaucoma. *Cochrane Database Syst Rev* 2021;3:CD005555.
- Perez CI, Chansangpetch S, Nguyen A, *et al*. How to predict intraocular pressure reduction after cataract surgery? A prospective study. *Curr Eye Res* 2019;44:623–31.
- Husain R, Clarke J, Seah S, *et al*. A review of trabeculectomy in East Asian people—the influence of race. *Nature Eye* 2005;19:243–52.
- Thomas R, Arun T, Muliylil J, *et al*. Outcome of laser peripheral iridotomy in chronic primary angle closure glaucoma. *Ophthalmic Surg Lasers* 1999;30:547–53.
- Tham Y-C, Li X, Wong TY, *et al*. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014;121:2081–90.